Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.
Curr Opin Urol. 2012 May;22(3):243-6. doi: 10.1097/MOU.0b013e328351dd57.
Active surveillance is now considered one of the preferred treatments for men with favorable risk prostate cancer (PCa). Unfortunately, 30-50% of men choosing active surveillance will progress and require therapy. In this context, we will present recent data on the efficacy of 5-alpha-reductase inhibitors (5-ARIs) in secondary prevention among men with low-risk PCa choosing active surveillance.
Two recent studies including a multicenter randomized controlled study demonstrate that 5-ARI may reduce the rate of clinical progression in low-risk PCa.
5-ARIs may play an important role in secondary prevention in low-risk PCa. These results should be interpreted with caution in view of the recent US Food and Drug Administration recommendation against PCa chemoprevention labeling for 5-ARIs.
主动监测目前被认为是治疗低危前列腺癌（PCa）患者的首选方法之一。不幸的是，30-50%选择主动监测的男性会出现进展并需要治疗。在此背景下，我们将介绍最近关于 5α-还原酶抑制剂（5-ARIs）在选择主动监测的低危 PCa 男性中进行二级预防的疗效的相关数据。
两项最近的研究，包括一项多中心随机对照研究，表明 5-ARI 可能降低低危 PCa 患者临床进展的发生率。
5-ARIs 可能在低危 PCa 的二级预防中发挥重要作用。鉴于最近美国食品和药物管理局（FDA）反对将 5-ARIs 用于 PCa 化学预防的标签建议，这些结果的解释应持谨慎态度。
